The Lancet. Oncology · 2026
Lymph node surgery and CDK4/6 inhibitors in early breast cancer: a pooled analysis from five randomised trials.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Pfob André, Pham Thi Hao, de Boniface Jana, Gentilini Oreste Davide, Loibl Sibylle, Schneeweiss Andreas, Postma Maarten, van Asselt Antoinette D I, Reimer Toralf, Heil Jörg
Аннотация
BACKGROUND: Omitting sentinel lymph node biopsy (SLNB) and completion axillary lymph node dissection (cALND) in early-stage breast cancer reduces morbidity without compromising overall survival or recurrence rates. However, reduced axillary surgery restricts staging information, impacting eligibility for CDK4/6 inhibitors. We evaluated the impact of omitting SLNB or cALND on CDK4/6 inhibitor eligibility and the associated benefits and harms.
METHODS: We used data from the SOUND, INSEMA, SENOMAC, monarchE, and NATALEE randomised trials. These five trials evaluated the safety of de-escalated lymph node surgery and adjuvant CDK4/6 inhibitors in patients with early breast cancer. The primary outcome was the number needed to diagnose and treat with CDK4/6 inhibitor-ie, number of axillary surgeries leading to adjuvant CDK4/6 inhibitor use, preventing one invasive disease-free survival event, distant disease-free survival event, or overall survival event at 5 years.
FINDINGS: Between Jan 31, 2015, and Dec 31, 2021, 19 541 patients were randomly assigned and analysed within five trials, of whom 19 475 (99·7%) were women and 66 (0·3%) were men; median follow-up was 57·2 months (IQR 44·1-81·6). For SLNB and ribociclib, the number needed to diagnose and treat for one prevented event was 123 for invasive disease-free survival, 129 for distant disease-free survival, and 345 for overall survival. For cALND and abemaciclib, the number needed to diagnose and treat for one prevented event was 106 invasive disease-free survival, 119 for distant disease-free survival, and 807 for overall survival.
INTERPRETATION: Performing SLNB or cALND solely to determine eligibility for CDK4/6 inhibition requires very high number needed to diagnose and treat, adds substantial morbidity, and is costly, with only marginal overall survival benefit.
FUNDING: None.
METHODS: We used data from the SOUND, INSEMA, SENOMAC, monarchE, and NATALEE randomised trials. These five trials evaluated the safety of de-escalated lymph node surgery and adjuvant CDK4/6 inhibitors in patients with early breast cancer. The primary outcome was the number needed to diagnose and treat with CDK4/6 inhibitor-ie, number of axillary surgeries leading to adjuvant CDK4/6 inhibitor use, preventing one invasive disease-free survival event, distant disease-free survival event, or overall survival event at 5 years.
FINDINGS: Between Jan 31, 2015, and Dec 31, 2021, 19 541 patients were randomly assigned and analysed within five trials, of whom 19 475 (99·7%) were women and 66 (0·3%) were men; median follow-up was 57·2 months (IQR 44·1-81·6). For SLNB and ribociclib, the number needed to diagnose and treat for one prevented event was 123 for invasive disease-free survival, 129 for distant disease-free survival, and 345 for overall survival. For cALND and abemaciclib, the number needed to diagnose and treat for one prevented event was 106 invasive disease-free survival, 119 for distant disease-free survival, and 807 for overall survival.
INTERPRETATION: Performing SLNB or cALND solely to determine eligibility for CDK4/6 inhibition requires very high number needed to diagnose and treat, adds substantial morbidity, and is costly, with only marginal overall survival benefit.
FUNDING: None.